Evidence map›Paper›PMID 34441819›Full record

ArticleJournal of clinical medicine2021

Supervised Machine Learning Approach to Identify Early Predictors of Poor Outcome in Patients with COVID-19 Presenting to a Large Quaternary Care Hospital in New York City.

Jason Zucker, Angela Gomez-Simmonds, Lawrence J Purpura, Sherif Shoucri, Elijah LaSota, Nicholas E Morley, Brit W Sovic, Marvin A Castellon, Deborah A Theodore, Logan L Bartram and 15 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Jason ZuckerDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0001-6987-6412
Angela Gomez-SimmondsDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Lawrence J PurpuraDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Sherif ShoucriDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Elijah LaSotaTulane University School of Medicine, Tulane Medical Center, New Orleans, LA 70112, USA.
Nicholas E MorleyColumbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.
Brit W SovicDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Marvin A CastellonDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Deborah A TheodoreDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Logan L BartramDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Benjamin A MikoDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Matthew L SchererDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Kathrine A MeyersAaron Diamond AIDS Research Center, Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
William C TurnerGeneral Internal Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Maureen KellyGeneral Internal Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Martina PavlicovaMailman School of Public Health, Columbia University Irving Medical Center, New York, NY 10032, USA.
Cale N BasarabaMailman School of Public Health, Columbia University Irving Medical Center, New York, NY 10032, USA.
Matthew R BaldwinDivision of Pulmonology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Daniel BrodieDivision of Pulmonology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Kristin M BurkartDivision of Pulmonology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Joan BathonDivision of Rheumatology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Anne-Catrin UhlemannDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Michael T YinDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Delivette CastorDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Magdalena E SobieszczykDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.
Columbia University Irving Medical Center · USAaron Diamond AIDS Research Center · USColumbia University · USIcahn School of Medicine at Mount Sinai · USTulane University · US

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Columbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4M
Columbia Integrated Training Program in Infectious Diseases ResearchT32AI100852 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK, Anne-Catrin Uhlemann · 2013 to 2026
$2.2M
Harnessing Bioinformatics for HIV Prevention: Understanding Persistence in Comprehensive HIV Prevention ServicesK23AI150378 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZUCKER, JASON · 2020 to 2024
$960k
NIAID NIH HHS K23 AI150378NIAID NIH HHS T32 AI100852NIAID NIH HHS U01 AI069470NIAID NIH HHS UM1 AI069470NIH HHS 5UM1AI069470-14NIH HHS K23AI150378NIH HHS L30AI133789
6 · The paper itself

Abstract

backgroundThe progression of clinical manifestations in patients with coronavirus disease 2019 (COVID-19) highlights the need to account for symptom duration at the time of hospital presentation in decision-making algorithms.

methodsWe performed a nested case-control analysis of 4103 adult patients with COVID-19 and at least 28 days of follow-up who presented to a New York City medical center. Multivariable logistic regression and classification and regression tree (CART) analysis were used to identify predictors of poor outcome.

resultsPatients presenting to the hospital earlier in their disease course were older, had more comorbidities, and a greater proportion decompensated (<4 days, 41%; 4-8 days, 31%; >8 days, 26%). The first recorded oxygen delivery method was the most important predictor of decompensation overall in CART analysis. In patients with symptoms for <4, 4-8, and >8 days, requiring at least non-rebreather, age ≥ 63 years, and neutrophil/lymphocyte ratio ≥ 5.1; requiring at least non-rebreather, IL-6 ≥ 24.7 pg/mL, and D-dimer ≥ 2.4 µg/mL; and IL-6 ≥ 64.3 pg/mL, requiring non-rebreather, and CRP ≥ 152.5 mg/mL in predictive models were independently associated with poor outcome, respectively.

conclusionSymptom duration in tandem with initial clinical and laboratory markers can be used to identify patients with COVID-19 at increased risk for poor outcomes.

Indexed as

COVIDmachine learningoutcomes

Identifiers

PMID34441819
PMCPMC8397083
OpenAlexW3189899117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.